Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.08 -5.4%	$2.97	$1.05 ▼ $3.97	$345.93M	1.92	592,965 shs	261,995 shs
ALDX Aldeyra Therapeutics	$5.84 -0.3%	$4.97	$1.14 ▼ $7.20	$349.82M	0.76	1.17 million shs	453,141 shs
FULC Fulcrum Therapeutics	$6.48 -2.6%	$7.11	$2.32 ▼ $9.30	$350.52M	2.47	577,530 shs	181,855 shs
OKYO OKYO Pharma	$2.35 +3.1%	$2.70	$0.90 ▼ $3.35	$88.38M	-0.09	170,705 shs	152,538 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+0.62%	+4.51%	+12.87%	+4.68%	+10.75%
ALDX Aldeyra Therapeutics	+0.17%	-0.34%	+15.13%	+171.30%	+11.62%
FULC Fulcrum Therapeutics	+0.30%	+1.99%	-12.38%	-3.06%	-25.03%
OKYO OKYO Pharma	+0.88%	-2.15%	-10.24%	+23.49%	+109.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.3331 of 5 stars	3.5	1.0	0.6	0.8	0.6
ALDX Aldeyra Therapeutics	1.8199 of 5 stars	3.3	1.0	2.0	1.7	0.6
FULC Fulcrum Therapeutics	0.8746 of 5 stars	2.3	1.0	2.2	1.7	0.0
OKYO OKYO Pharma	3.0989 of 5 stars	3.5	5.0	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	152.03% Upside
ALDX Aldeyra Therapeutics	2.67	Moderate Buy	$9.50	62.67% Upside
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	16.84% Upside
OKYO OKYO Pharma	3.00	Buy	$7.00	197.87% Upside

Current Analyst Ratings Breakdown

Latest OKYO, ADCT, ALDX, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/8/2025	ALDX Aldeyra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$77.25M	4.48	N/A	N/A	($1.77) per share	-1.74
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.92 per share	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.57	N/A	N/A	N/A	-220.00%	N/A	-53.73%	11/6/2025 (Estimated)
ALDX Aldeyra Therapeutics	-$55.85M	-$0.85	N/A	N/A	N/A	N/A	-73.63%	-50.61%	11/6/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	11/12/2025 (Estimated)
OKYO OKYO Pharma	-$4.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest OKYO, ADCT, ALDX, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	-$0.50	-$0.14	-$0.50	$17.82 million	$18.84 million
8/7/2025	Q2 2025	ALDX Aldeyra Therapeutics	-$0.21	-$0.16	+$0.05	-$0.16	$1.08 million	N/A
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.93	4.66
ALDX Aldeyra Therapeutics	N/A	2.86	2.86
FULC Fulcrum Therapeutics	N/A	24.42	24.42
OKYO OKYO Pharma	N/A	0.40	0.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
ALDX Aldeyra Therapeutics	59.71%
FULC Fulcrum Therapeutics	89.83%
OKYO OKYO Pharma	2.97%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
ALDX Aldeyra Therapeutics	9.60%
FULC Fulcrum Therapeutics	7.00%
OKYO OKYO Pharma	40.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	112.50 million	106.42 million	Optionable
ALDX Aldeyra Therapeutics	10	59.90 million	54.15 million	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable
OKYO OKYO Pharma	7	37.61 million	22.39 million	Not Optionable

OKYO, ADCT, ALDX, and FULC Headlines

Recent News About These Companies

OKYO Pharma (NASDAQ:OKYO) Raised to "Hold" at Wall Street Zen

August 10, 2025 | marketbeat.com

Neuropathic corneal pain reduced in phase 2 trial of urcosimod

August 7, 2025 | healio.comH

Dauntless Investment Group LLC Invests $2.53 Million in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO)

July 29, 2025 | marketbeat.com

OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI

July 19, 2025 | proactiveinvestors.com

OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI

July 19, 2025 | proactiveinvestors.com

OKYO Slides Despite Fresh R&D Funding

July 17, 2025 | baystreet.ca

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

July 17, 2025 | finance.yahoo.com

OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development

July 17, 2025 | tipranks.com

OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy

July 17, 2025 | proactiveinvestors.com

OKYO reports top-line data from neuropathic corneal pain therapy trial

July 17, 2025 | finance.yahoo.com

Okyo sets sights on first approval in neuropathic eye pain after phase 2 win

July 16, 2025 | fiercebiotech.comF

OKYO Pharma shares surge following promising Phase 2 data for eye pain treatment

July 16, 2025 | msn.com

Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation

July 16, 2025 | tipranks.com

OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain

July 16, 2025 | tipranks.com

OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain

July 16, 2025 | proactiveinvestors.com

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

July 16, 2025 | globenewswire.com

OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders

June 14, 2025 | uk.finance.yahoo.com

OKYO Pharma to Present at the Bio International Convention

June 11, 2025 | manilatimes.netM

OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts

June 11, 2025 | proactiveinvestors.com

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited | OKYO Stock News

June 11, 2025 | gurufocus.com

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

June 11, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO, ADCT, ALDX, and FULC Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.08 -0.18 (-5.38%)

Closing price 03:59 PM Eastern

Extended Trading

$3.16 +0.09 (+2.76%)

As of 05:13 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Aldeyra Therapeutics NASDAQ:ALDX

$5.84 -0.02 (-0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$5.90 +0.07 (+1.11%)

As of 07:40 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Fulcrum Therapeutics NASDAQ:FULC

$6.48 -0.17 (-2.56%)

Closing price 04:00 PM Eastern

Extended Trading

$6.59 +0.11 (+1.70%)

As of 05:38 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

OKYO Pharma NASDAQ:OKYO

$2.35 +0.07 (+3.07%)

Closing price 04:00 PM Eastern

Extended Trading

$2.28 -0.08 (-3.19%)

As of 05:08 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time